INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three to four weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.

Inhibrx initiated a Phase 2 registration-enabling clinical trial for INBRX-101 using functional AAT as the primary endpoint for regulatory approval.

Learn more Phase 1 Trial Phase 2 Trial

INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

The Phase 1 trial for INBRX-109 is currently enrolling combination treatment cohorts in pancreatic adenocarcinoma, malignant pleural mesothelioma, Ewing sarcoma, and colorectal cancer.

The Phase 2 trial for INBRX-109 is currently enrolling patients with unresectable or metastatic conventional chondrosarcoma.

Learn more Phase 1 Trial Phase 2 Trial

INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40, which is currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Parts 2 and 4, single agent dose expansion and dose expansion in combination with Keytruda, are currently enrolling in the following tumor types:

• Solid Tumors
• Non-Small Cell Lung Cancer (NSCLC)
• Melanoma
• Head and Neck Cancer
• Gastric Cancer (GIST)
• Renal Cell Carcinoma (RCC)
• Urothelial Carcinoma

Learn more clinicaltrials.gov